Business Context and Reporting Period
This Form 8-K Current Report was filed by Tivic Health Systems, Inc. (not Valion Bio, Inc.) on June 25, 2025. The registrant is a Delaware corporation with its principal executive offices in Fremont, California. The filing serves as a Regulation FD disclosure regarding a specific corporate development.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a non-financial operational milestone.
Material Changes
The primary material event disclosed is the completion of the Optimization Study for the Company's non-invasive vagus nerve stimulation device. This operational update is detailed in a press release furnished as Exhibit 99.1.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The report contains forward-looking statements regarding future results, performance, and achievements based on management's current estimates.
- Risks and Uncertainties: Management explicitly states that actual results may differ materially from expectations due to known and unknown risks, uncertainties, and other factors.
- Legal Disclaimer: Information in Item 7.01 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability for the forward-looking content.
Investor Verification Checklist
- Verify the details of the completed Optimization Study by reviewing Exhibit 99.1 (the press release) attached to this filing.
- Confirm the Company's name is Tivic Health Systems, Inc. (Ticker: TIVC), as the input metadata referenced "Valion Bio, Inc."
- Review the Company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains no financial statements.
- Assess the specific risks outlined in the forward-looking statements section regarding the vagus nerve stimulation device.